Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
ENRICH trial expanded into Europe
February 3rd, 2005
Allos Therapeutics, Inc., (ALTH) announced the expansion into Europe of its phase III trial of the investigational radiation sensitizer Efaproxyn (efaproxiral) in patients with brain metastases originating from breast cancer. The company reported that the first ex-North American patient was enrolled yesterday in France. To date, five investigative sites have opened for enrollment in the EU, and another 65 ex-North American sites have committed to participate in the study. The phase III study, known as ENRICH (ENhancing Whole Brain Radiation Therapy In Patients with Breast Cancer and Hypoxic Brain Metastases), is designed to compare the effect of...
Source: Women's Health Weekly (2005-02-03)
|
